U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H20FN5O2.C4H6O4
Molecular Weight 475.4701
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRELAGLIPTIN SUCCINATE

SMILES

OC(=O)CCC(O)=O.CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC(F)=C3)C#N)C1=O

InChI

InChIKey=OGCNTTUPLQTBJI-XFULWGLBSA-N
InChI=1S/C18H20FN5O2.C4H6O4/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20;5-3(6)1-2-4(7)8/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3;1-2H2,(H,5,6)(H,7,8)/t15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H20FN5O2
Molecular Weight 357.3821
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes mellitus. Trelagliptin (as the salt Trelagliptin succinate) was approved for use in Japan in March 2015. Takeda, the company that developed Trelagliptin, chose to not get approval for the drug in the USA and EU.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.0 nM [IC50]
4.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Zafatek
PubMed

PubMed

TitleDatePubMed
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
2016
Patents

Sample Use Guides

In Vivo Use Guide
Usually, for adults, 100 mg of trelagliptin is orally administered once a week
Route of Administration: Oral
In Vitro Use Guide
Trelagliptin (1 M) were incubated 0, 5, 15, 30 minute at 37 °C in phosphate buffer (50 mM, pH 7.4) containing rat or human liver microsomes (1 mg/mL protein) and NADPH (4 mM). Metabolic stability of Trelagliptin was assayed by LC/MS
Substance Class Chemical
Created
by admin
on Mon Oct 21 23:26:26 UTC 2019
Edited
by admin
on Mon Oct 21 23:26:26 UTC 2019
Record UNII
4118932Z90
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRELAGLIPTIN SUCCINATE
USAN   WHO-DD  
USAN  
Official Name English
SYR-111472 SUCCINATE
Code English
BUTANEDIOIC ACID, COMPD. WITH 2-((6-((3R)-3-AMINO-1-PIPERIDINYL)-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL)METHYL)-4-FLUOROBENZONITRILE (1:1)
Common Name English
SYR111472 SUCCINATE
Code English
SYR-472
Code English
TRELAGLIPTIN SUCCINATE [USAN]
Common Name English
TRELAGLIPTIN SUCCINATE [WHO-DD]
Common Name English
ZAFATEK
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C98086
Created by admin on Mon Oct 21 23:26:26 UTC 2019 , Edited by admin on Mon Oct 21 23:26:26 UTC 2019
Code System Code Type Description
NCI_THESAURUS
C152724
Created by admin on Mon Oct 21 23:26:26 UTC 2019 , Edited by admin on Mon Oct 21 23:26:26 UTC 2019
PRIMARY
JAPANESE REVIEW
ZAFATEK
Created by admin on Mon Oct 21 23:26:26 UTC 2019 , Edited by admin on Mon Oct 21 23:26:26 UTC 2019
PRIMARY APPROVE MARCH 2015
EVMPD
SUB179791
Created by admin on Mon Oct 21 23:26:26 UTC 2019 , Edited by admin on Mon Oct 21 23:26:26 UTC 2019
PRIMARY
CAS
1029877-94-8
Created by admin on Mon Oct 21 23:26:26 UTC 2019 , Edited by admin on Mon Oct 21 23:26:26 UTC 2019
PRIMARY
EPA CompTox
1029877-94-8
Created by admin on Mon Oct 21 23:26:26 UTC 2019 , Edited by admin on Mon Oct 21 23:26:26 UTC 2019
PRIMARY
ChEMBL
CHEMBL1650443
Created by admin on Mon Oct 21 23:26:26 UTC 2019 , Edited by admin on Mon Oct 21 23:26:26 UTC 2019
PRIMARY
PUBCHEM
44183569
Created by admin on Mon Oct 21 23:26:26 UTC 2019 , Edited by admin on Mon Oct 21 23:26:26 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY